Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

被引：0
|
作者：
Galsky, Matt D.
Daneshmand, Siamak
Lewis, Sara C.
Chan, Kevin G.
Dorff, Tanya B.
Cetnar, Jeremy Paul
Mamtani, Ronac
Kyriakopoulos, Christos
Gogerly-Moragoda, Mahalya
Izadmehr, Sudeh
Yu, Menggang
Zhao, Qianqian
Jun, Tomi
Mehrazin, Reza
Sfakianos, John P.
Pal, Sumanta Monty
机构：
[1] Mt Sinai, Tisch Canc Inst, New York, NY USA
[2] USC, Norris Comprehens Canc Ctr, USC Inst Urol, Los Angeles, CA USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Univ Wisconsin, Madison, WI USA
[10] Sema4, Stamford, CT USA
[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[12] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
447
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
    Galsky, Matt D.
    Daneshmand, Siamak
    Chan, Kevin G.
    Dorff, Tanya B.
    Cetnar, Jeremy Paul
    Neil, Brock O.
    D'souza, Anishka
    Mamtani, Ronac
    Kyriakopoulos, Christos
    Garcia, Philip
    Izadmehr, Sudeh
    Yu, Menggang
    Zhao, Qianqian
    Mehrazin, Reza
    Lewis, Sara C.
    Sfakianos, John
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Galsky, Matthew D.
    Daneshmand, Siamak
    Izadmehr, Sudeh
    Gonzalez-Kozlova, Edgar
    Chan, Kevin G.
    Lewis, Sara
    Achkar, Bassam El
    Dorff, Tanya B.
    Cetnar, Jeremy Paul
    Neil, Brock O.
    D'Souza, Anishka
    Mamtani, Ronac
    Kyriakopoulos, Christos
    Jun, Tomi
    Gogerly-Moragoda, Mahalya
    Brody, Rachel
    Xie, Hui
    Nie, Kai
    Kelly, Geoffrey
    Horwitz, Amir
    Kinoshita, Yayoi
    Ellis, Ethan
    Nose, Yohei
    Ioannou, Giorgio
    Cabal, Rafael
    Haines, G. Kenneth
    Wang, Li
    Mouw, Kent W.
    Samstein, Robert M.
    Mehrazin, Reza
    Bhardwaj, Nina
    Yu, Menggang
    Zhao, Qianqian
    Kim-Schulze, Seunghee
    Sebra, Robert
    Zhu, Jun
    Gnjatic, Sacha
    Sfakianos, John
    Pal, Sumanta K.
    NATURE MEDICINE, 2023, 29 (11) : 2825 - +
  • [3] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Matthew D. Galsky
    Siamak Daneshmand
    Sudeh Izadmehr
    Edgar Gonzalez-Kozlova
    Kevin G. Chan
    Sara Lewis
    Bassam El Achkar
    Tanya B. Dorff
    Jeremy Paul Cetnar
    Brock O. Neil
    Anishka D’Souza
    Ronac Mamtani
    Christos Kyriakopoulos
    Tomi Jun
    Mahalya Gogerly-Moragoda
    Rachel Brody
    Hui Xie
    Kai Nie
    Geoffrey Kelly
    Amir Horowitz
    Yayoi Kinoshita
    Ethan Ellis
    Yohei Nose
    Giorgio Ioannou
    Rafael Cabal
    Diane M. Del Valle
    G. Kenneth Haines
    Li Wang
    Kent W. Mouw
    Robert M. Samstein
    Reza Mehrazin
    Nina Bhardwaj
    Menggang Yu
    Qianqian Zhao
    Seunghee Kim-Schulze
    Robert Sebra
    Jun Zhu
    Sacha Gnjatic
    John Sfakianos
    Sumanta K. Pal
    Nature Medicine, 2023, 29 : 2825 - 2834
  • [4] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Moschini, Marco
    Necchi, Andrea
    Montorsi, Francesco
    EUROPEAN UROLOGY, 2024, 85 (05) : 500 - 501
  • [5] Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Matthew D. Galsky
    Siamak Daneshmand
    Sudeh Izadmehr
    Edgar Gonzalez-Kozlova
    Kevin G. Chan
    Sara Lewis
    Bassam El Achkar
    Tanya B. Dorff
    Jeremy Paul Cetnar
    Brock O. Neil
    Anishka D’Souza
    Ronac Mamtani
    Christos Kyriakopoulos
    Tomi Jun
    Mahalya Gogerly-Moragoda
    Rachel Brody
    Hui Xie
    Kai Nie
    Geoffrey Kelly
    Amir Horowitz
    Yayoi Kinoshita
    Ethan Ellis
    Yohei Nose
    Giorgio Ioannou
    Rafael Cabal
    Diane M. Del Valle
    G. Kenneth Haines
    Li Wang
    Kent W. Mouw
    Robert M. Samstein
    Reza Mehrazin
    Nina Bhardwaj
    Menggang Yu
    Qianqian Zhao
    Seunghee Kim-Schulze
    Robert Sebra
    Jun Zhu
    Sacha Gnjatic
    John Sfakianos
    Sumanta K. Pal
    Nature Medicine, 2024, 30 : 1211 - 1211
  • [6] Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
    Tong, Z.
    Fu, G.
    Zhou, F.
    Liu, X.
    Xue, X.
    Zhang, H.
    Wang, Y.
    Zhu, X.
    Gao, Y.
    Liu, L.
    Bao, X.
    Zheng, Y.
    Fang, W.
    Zhao, P.
    Jin, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1210 - S1210
  • [7] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)
    Galsky, Matthew D.
    Daneshmand, Siamak
    Izadmehr, Sudeh
    Gonzalez-Kozlova, Edgar
    Chan, Kevin G.
    Lewis, Sara
    Achkar, Bassam El
    Dorff, Tanya B.
    Cetnar, Jeremy Paul
    Neil, Brock O.
    D'Souza, Anishka
    Mamtani, Ronac
    Kyriakopoulos, Christos
    Jun, Tomi
    Gogerly-Moragoda, Mahalya
    Brody, Rachel
    Xie, Hui
    Nie, Kai
    Kelly, Geoffrey
    Horowitz, Amir
    Kinoshita, Yayoi
    Ellis, Ethan
    Nose, Yohei
    Ioannou, Giorgio
    Cabal, Rafael
    Del Valle, Diane M.
    Haines, G. Kenneth
    Wang, Li
    Mouw, Kent W.
    Samstein, Robert M.
    Mehrazin, Reza
    Bhardwaj, Nina
    Yu, Menggang
    Zhao, Qianqian
    Kim-Schulze, Seunghee
    Sebra, Robert
    Zhu, Jun
    Gnjatic, Sacha
    Sfakianos, John
    Pal, Sumanta K.
    NATURE MEDICINE, 2024, 30 (4) : 1211 - 1211
  • [8] Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Balar, Arjun Vasant
    Iyer, Gopa
    Apolo, Andrea Borghese
    Regazzi, Ashley Marie
    Garcia-Grossman, Ilana Rebecca
    Pendse, Deepa
    Ostrovnaya, Irina
    Chou, Joanne F.
    Bochner, Bernard
    Dalbagni, Guido
    Herr, Harry W.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.
    Gupta, Shilpa
    Agarwal, Neeraj
    Konety, Badrinath R.
    Weight, Christopher J.
    Thyagarajan, Bharat
    Murugan, Paari J.
    Koopmeiners, Joseph S.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
    Guercio, Brendan John
    Pietzak, Eugene J.
    Brown, Samantha
    Chen, Jie-Fu
    Peters, Vanessa
    Regazzi, Ashley Marie
    Aggen, David Henry
    Donahue, Timothy F.
    Goh, Alvin C.
    Cha, Eugene K.
    Donat, S. Machele
    Dalbagni, Guido
    Bochner, Bernard H.
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Iyer, Gopa
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat A.
    Rosenberg, Jonathan E.
    Teo, Min Yuen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345